Extremities

Ground Breaking Research On Tyber Medical’s BioTy™, Antimicrobial Nanotopography, To Be Presented At The American Orthopaedic Foot And Ankle Society’s Annual Meeting

MORRISTOWN, N.J., July 19, 2016 /PRNewswire/ — Tyber Medical, LLC, a company focused on providing rapid private label commercialization with innovative orthopedic and spine devices including bioengineered surfaces, announces a podium presentation on BioTy™, an antimicrobial nanotopography, at the 2016 AOFAS annual meeting in Toronto, Canada.

Logo – http://photos.prnewswire.com/prnh/20160719/390937LOGO

In vitro results of Tyber Medical’s patented BioTy Modified Surface Treatment technology will be presented by Thomas J. Webster, Ph.D., Art Zafiropoulo Chair and Professor of Chemical Engineering, Northeastern University at the 2016 AOFAS meeting in Toronto, Canada on Saturday, July 23rd.  Additionally, the full in vitro results are pending publication in theInternational Journal of Nanomedicine as well as Foot and Ankle International.  Tyber Medical’s  BioTy Modified Surface Treatment is FDA cleared on the Tyber Medical headless screws, headed screws, and snap-off screws and is indicated for use in bone reconstruction, osteotomies, arthrodesis, joint fusion, fracture repair, and fracture fixation of bones appropriate for the size of the device.

“The antimicrobial properties of BioTy®, without the use of pharmacological agents, are revolutionary.  With this innovative technology platform and its versatility, bacteria reduction is possible across multiple medical devices” commented Jeff Tyber, President and CEO of Tyber Medical, LLC.

“We are proud of the work that the expert team at Tyber Medical and our research partners at Northeastern University have done to demonstrate that BioTy™ has the potential to deliver a 95% reduction in bacteria adherence on titanium surfaces” stated Rui J. Ferreira, Vice President of Research and Development.

The BioTy™ platform, which has already been cleared by the FDA, is currently under review to expand its claims.  The company expects to launch their first products in the fourth quarter of 2016 and is exploring additional commercialization opportunities.

Please contact Eric Dickson (edickson@tybermed.com), Global Director of Business Development, to schedule a meeting at AOFAS 2016 or to inquire about Tyber Medical private labeled products or technology.

About Tyber Medical:

Tyber Medical, LLC, Morristown, New Jersey, a rapid commercialization device company, is creating new pathways to regulatory approved bioengineered implants and instruments for orthopedic companies, large distributors, and hospital organizations. Tyber Medical designs and develops full class II orthopedic systems; verifies and validates those systems using a QSR and ISO 13485 certified quality system; and pursues and maintains both US (FDA 510k) and OUS (CE Mark) regulatory approvals. Current products include the opening osteotomy system, headless and headed compression screws, snap-off screws, cervical plating system, lateral retractor system and spinal interbody spacers featuring both standard sterile and non-sterile PEEK andTyPEEK®, a proprietary titanium plasma sprayed PEEK. The company is also developing BioTy™, a nanotopography surface modification which limits the adherence of bacteria to implants.  For more information, please visit www.tybermedical.com.

The TyWedge™ System and Spinal Interbody Spacers are made with PEEK-OPTIMA® from Invibio® Biomaterial Solutions.

Contact: 

Eric J. Dickson
89 Headquarters Plaza North, #1464
Morristown, New Jersey 07960
(866) 761-0933
edickson@tybermed.com

SOURCE Tyber Medical, LLC

Related Links

http://www.tybermedical.com

Drue

Drue is Managing Partner for The De Angelis Group.

Related Articles

Back to top button